Floatz logo

Imu-201 (Pd1-Vaxx)

Large Cell Carcinoma Lung

Imugene LimitedPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Large Cell Carcinoma Lung cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 4A
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Gefetinib
National Cancer Institute (NCI)
Phase 3BB
Vinorelbine
AIO-Studien-gGmbH
Phase 3BB

View all 34 →

Same molecule, other indications

Imu-201 (Pd1-Vaxx) is also rated in:

colorectal cancerDormant
CC
Indicative ·
46 / 100
View asset →
squamous cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
lung adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →